Stock Track | TG Therapeutics Plummets 5.66% Despite Strong Q3 Results and Raised Guidance

Stock Track11-03

TG Therapeutics (NASDAQ: TGTX) experienced a surprising 5.66% plunge in pre-market trading on Monday, despite reporting robust third-quarter results that surpassed analyst expectations. The biopharmaceutical company's stock movement contradicts its impressive financial performance, leaving investors puzzled.

The company reported a remarkable quarterly earnings of $2.43 per share, significantly beating the analyst consensus estimate of $0.22. This represents a substantial 12,050% increase from the $0.02 per share reported in the same period last year. TG Therapeutics also posted quarterly sales of $161.709 million, exceeding the analyst consensus estimate of $152.169 million by 6.27%. The revenue figure marks a 92.79% year-over-year increase from $83.879 million.

Adding to the positive news, TG Therapeutics raised its full-year guidance. The company increased its 2025 global revenue target to approximately $600 million and raised the BRIUMVI U.S. net revenue target to about $585 million, citing strong market demand. Furthermore, the company completed a $100 million share repurchase program and authorized an additional $100 million for future repurchases. Despite these encouraging developments, the stock's pre-market decline suggests that investors may be engaging in profit-taking or harboring concerns not immediately apparent from the earnings report.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194412638?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194412638","market":"sg","top_or_hot":-1,"title":"Stock Track | TG Therapeutics Plummets 5.66% Despite Strong Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>TG Therapeutics (NASDAQ: TGTX) experienced a surprising 5.66% plunge in pre-market trading on Monday, despite reporting robust third-quarter results that surpassed analyst expectations. The biopharmaceutical company's stock movement contradicts its impressive financial performance, leaving investors puzzled.</p>\n\n<p>The company reported a remarkable quarterly earnings of $2.43 per share, significantly beating the analyst consensus estimate of $0.22. This represents a substantial 12,050% increase from the $0.02 per share reported in the same period last year. TG Therapeutics also posted quarterly sales of $161.709 million, exceeding the analyst consensus estimate of $152.169 million by 6.27%. The revenue figure marks a 92.79% year-over-year increase from $83.879 million.</p>\n\n<p>Adding to the positive news, TG Therapeutics raised its full-year guidance. The company increased its 2025 global revenue target to approximately $600 million and raised the BRIUMVI U.S. net revenue target to about $585 million, citing strong market demand. Furthermore, the company completed a $100 million share repurchase program and authorized an additional $100 million for future repurchases. Despite these encouraging developments, the stock's pre-market decline suggests that investors may be engaging in profit-taking or harboring concerns not immediately apparent from the earnings report.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TG Therapeutics Plummets 5.66% Despite Strong Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TG Therapeutics Plummets 5.66% Despite Strong Q3 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-03 22:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TG Therapeutics (NASDAQ: TGTX) experienced a surprising 5.66% plunge in pre-market trading on Monday, despite reporting robust third-quarter results that surpassed analyst expectations. The biopharmaceutical company's stock movement contradicts its impressive financial performance, leaving investors puzzled.</p>\n\n<p>The company reported a remarkable quarterly earnings of $2.43 per share, significantly beating the analyst consensus estimate of $0.22. This represents a substantial 12,050% increase from the $0.02 per share reported in the same period last year. TG Therapeutics also posted quarterly sales of $161.709 million, exceeding the analyst consensus estimate of $152.169 million by 6.27%. The revenue figure marks a 92.79% year-over-year increase from $83.879 million.</p>\n\n<p>Adding to the positive news, TG Therapeutics raised its full-year guidance. The company increased its 2025 global revenue target to approximately $600 million and raised the BRIUMVI U.S. net revenue target to about $585 million, citing strong market demand. Furthermore, the company completed a $100 million share repurchase program and authorized an additional $100 million for future repurchases. Despite these encouraging developments, the stock's pre-market decline suggests that investors may be engaging in profit-taking or harboring concerns not immediately apparent from the earnings report.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1194412638","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194412638","pubTimestamp":1762180549,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TG Therapeutics (NASDAQ: TGTX) experienced a surprising 5.66% plunge in pre-market trading on Monday, despite reporting robust third-quarter results that surpassed analyst expectations. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"个股追踪|TG Therapeutics暴跌5.66%尽管Q3业绩强劲且指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"TG Therapeutics (NASDAQ: TGTX) experienced a surprising 5.66% plunge in pre-market trading on Monday, despite reporting robust third-quarter results that surpassed analyst expectations. The biopharmaceutical company's stock movement contradicts its impressive financial performance, leaving investors puzzled.\nThe company reported a remarkable quarterly earnings of $2.43 per share, significantly beating the analyst consensus estimate of $0.22. This represents a substantial 12,050% increase from the $0.02 per share reported in the same period last year. TG Therapeutics also posted quarterly sales of $161.709 million, exceeding the analyst consensus estimate of $152.169 million by 6.27%. The revenue figure marks a 92.79% year-over-year increase from $83.879 million.\nAdding to the positive news, TG Therapeutics raised its full-year guidance. The company increased its 2025 global revenue target to approximately $600 million and raised the BRIUMVI U.S. net revenue target to about $585 million, citing strong market demand. Furthermore, the company completed a $100 million share repurchase program and authorized an additional $100 million for future repurchases. Despite these encouraging developments, the stock's pre-market decline suggests that investors may be engaging in profit-taking or harboring concerns not immediately apparent from the earnings report.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194412638","isCrawlerRequest":true}